Skip to content

Vaxcyte, Inc. PCVX Income Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$312.78M+111%$242.06M+81.2%$209.93M+79.5%$194.18M+47.7%$148.13M+56.6%
$33.07M+1.3%$32.22M+12.8%$32.45M+41.1%$32.04M+49.2%$32.66M+64.2%
$345.85M+91.3%$274.28M+69.1%$242.38M+73.2%$226.22M+47.9%$180.79M+57.9%
$345.85M+91.3%$274.28M+69.1%$242.38M+73.2%$226.22M+47.9%$180.79M+57.9%
-$345.85M-91.3%-$274.28M-69.1%-$242.38M-73.2%-$226.22M-47.9%-$180.79M-57.9%
$26.61M-19.2%$26.45M-27.4%$29.26M+4.3%$31.07M+30.5%$32.94M+52.0%
$25.23M-37.0%$27.78M+10.7%$29.55M-19.7%$59.65M+146%$40.08M+106%
-$320.62M-128%-$246.51M-79.8%-$212.83M-106%-$166.57M-29.4%-$140.72M-48.1%
-$2.30-121%-$1.80-76.5%-$1.56-88.0%-$1.22-10.9%-$1.04-22.4%
-$2.30-121%-$1.80-76.5%-$1.56-88.0%-$1.22-10.9%-$1.04-22.4%
139.5M+2.8%136.1M+11.6%136.2M+10.1%136M+16.0%135.7M+21.5%
139.5M+2.8%136.1M+11.6%136.2M+10.1%136M+16.0%135.7M+21.5%
$0$0$0$0
-$1.38M-119%$1.33M+112%$291K-96.7%$28.57M+6,045%$7.14M+422%
-$345.85M-91.3%-$274.28M-69.1%-$242.38M-73.2%-$226.22M-47.9%-$180.79M-57.9%
-$342.9M-92.8%-$266.79M-67.5%-$239.32M-73.2%-$223.34M-47.3%-$177.84M-56.7%
-$342.9M-92.8%-$266.79M-67.5%-$239.32M-73.2%-$223.34M-47.3%-$177.84M-56.7%
-$345.85M-91.3%-$274.28M-69.1%-$242.38M-73.2%-$226.22M-47.9%-$180.79M-57.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Vaxcyte, Inc. profitable?
Vaxcyte, Inc. is not currently profitable: it reported a net loss of $946.5M over the trailing twelve months.
What is Vaxcyte, Inc.'s earnings per share?
Vaxcyte, Inc.'s diluted EPS over the trailing twelve months is $-6.88.
Where does Vaxcyte, Inc.'s income statement data come from?
Every line is extracted from Vaxcyte, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.